Internal Medicine, Hematology & Oncology · Boston, MA
NPI
1669765988
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
55 Fruit St
Boston, MA, 02114
Phone (617) 643-6214
Groups this clinician bills Medicare through
Medicare paid, 2024
$32K
385 services
Medicare patients, 2024
111
Average age 72
Drug cost, 2024
$1.0M
78 prescriptions
Company payments, 2025
$83K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hanny T Al-Samkari was code 99215 (office e&m - established), 88 times for 52 patients. In total Hanny T Al-Samkari billed 385 services in 9 codes, and Medicare paid $32K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-05-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 88 | 52 | $149.37 | $13K |
| 99215 Office E&M - Established | Facility | 74 | 37 | $120.09 | $8,887 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 68 | 47 | $13.62 | $926 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 55 | 33 | $13.57 | $746 |
| 99233 Hospital E&M - Subsequent | Facility | 35 | 23 | $98.83 | $3,459 |
| 99223 Hospital E&M - Initial | Facility | 21 | 21 | $144.35 | $3,031 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 16 | 14 | $26.11 | $418 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 13 | 12 | $27.41 | $356 |
By year: 2022 $27K for 290 services; 2023 $27K for 258 services; 2024 $32K for 385 services.
Medicare prescription drug claims, 2024
In 2024, the drug Hanny T Al-Samkari prescribed most often to Medicare patients was Pyrukynd (Mitapivat Sulfate), with 38 prescriptions and refills. In total Hanny T Al-Samkari wrote 78 Medicare prescriptions that cost $1.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pyrukynd Mitapivat Sulfate | 38 | 42 | Under 11 | $1.0M |
Brand drugs: 45 claims; generic drugs: 33 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hanny T Al-Samkari $83K ($69K in general payments such as food, travel and fees and $13K for research) from 9 companies. The largest payer was Novartis Pharmaceuticals Corporation with $23K.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 13 | $23K |
| Vertex Pharmaceuticals Incorporated VRTX | 5 | $17K |
| Alnylam Pharmaceuticals Inc. ALNY | 9 | $13K |
| Agios Pharmaceuticals, Inc. AGIO | 5 | $8,662 |
| Amgen Inc. AMGN | 2 | $6,986 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $4,550 |
| Genzyme Corporation SNY | 1 | $4,504 |
| Pharmacosmos Therapeutics Inc. | 4 | $4,367 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.